A biotechnology company focused on advancing institutional blockchain adoption through the Canton network and Canton Coin, while also developing innovative pharmaceutical formulations including GV104, a buccal film technology for treating respiratory and nervous system depression, and GV023, an oral formulation of infliximab designed to eliminate the treatment burden of intravenous infusions.